Partial
Partially Aligned
Patient Risk:
Low
Summary
Some claims (oral administration, tyrosine kinase inhibitor class, FDA indication for adult CML after resistance/intolerance to prior therapy) are consistent with the provided label excerpts, but several claims are not supported by the supplied prescribing information (e.g., FDA 2012 approval date and patent/expiration statements). The provided label excerpts do not cover approval date or patent counts/claims, so these cannot be verified against the label.
Category Scores
Accurate Statements
Bosulif is an oral medication.
Label 2.1: “The recommended dosage is taken orally once daily with food.”
Bosulif is approved by the FDA for the treatment of adult patients with chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including tyrosine kinase inhibitors.
Label 1: Adult patients with AP or BP Ph+ CML with resistance or intolerance to prior therapy; and CP Ph+ CML resistant or intolerant to prior therapy.
Unsupported Statements
Bosulif (bosutinib) is a medication used to treat certain types of leukemia.
The provided excerpts specify CML indications but do not explicitly support the broader wording “certain types of leukemia” as a standalone claim.
Bosulif belongs to the class of drugs known as tyrosine kinase inhibitors.
The provided label excerpts do not explicitly state that BOSULIF is a tyrosine kinase inhibitor or name the drug class.
Tyrosine kinase inhibitors work by blocking specific enzymes that contribute to cancer cell growth.
The provided label excerpts do not describe the mechanism of action in these terms.
Bosulif was approved by the U.S. Food and Drug Administration (FDA) in 2012.
The provided label excerpts do not include an FDA approval year.
Bosulif has a total of 14 patents listed in the United States.
Patent counts are not addressed in the provided label excerpts.
U.S. Patent 7,405,409 is titled "Benzylpiperidine derivatives and their use as tyrosine kinase inhibitors."
Patent bibliographic details are not addressed in the provided label excerpts.
U.S. Patent 7,405,409 covers the chemical structure and method of synthesis of bosutinib.
Patent scope is not addressed in the provided label excerpts.
U.S. Patent 7,405,409 covers the use of bosutinib as a tyrosine kinase inhibitor.
Patent scope is not addressed in the provided label excerpts.
U.S. Patent 7,405,409 was filed in 2005.
Patent filing dates are not addressed in the provided label excerpts.
U.S. Patent 7,964,679 is titled "Methods of treating cancer using bosutinib."
Patent bibliographic details are not addressed in the provided label excerpts.
U.S. Patent 7,964,679 covers the use of bosutinib in treating various types of cancer, including CML.
Patent scope is not addressed in the provided label excerpts.
U.S. Patent 7,964,679 was filed in 2007.
Patent filing dates are not addressed in the provided label excerpts.
U.S. Patent 8,759,805 is titled "Bosutinib formulations and methods of use."
Patent bibliographic details are not addressed in the provided label excerpts.
U.S. Patent 8,759,805 covers the formulation and delivery of bosutinib.
Patent scope is not addressed in the provided label excerpts.
U.S. Patent 8,759,805 covers use in oral dosage forms.
Patent scope is not addressed in the provided label excerpts.
U.S. Patent 9,341,444 is titled "Methods of treating cancer using bosutinib in combination with other agents."
Patent bibliographic details are not addressed in the provided label excerpts.
U.S. Patent 9,341,444 covers the use of bosutinib in combination with other cancer therapies.
Patent scope is not addressed in the provided label excerpts.
The patents covering Bosulif are set to expire at various dates between 2026 and 2033.
Patent expiration timing is not addressed in the provided label excerpts.
U.S. Patent 7,405,409 is set to expire on August 28, 2026.
Patent expiration dates are not addressed in the provided label excerpts.
The expiration of the patents covering Bosulif will likely lead to increased generic competition for Bosulif.
The provided label excerpts do not address generic competition or patent-related market outcomes.
Increased generic competition for Bosulif is expected to potentially reduce the medication's price and increase access to patients.
The provided label excerpts do not address pricing/access expectations.
The exact timing and impact of generic competition will depend on factors including the approval of generic versions of Bosulif.
The provided label excerpts do not address generic approval timing or its impact.
The exact timing and impact of generic competition will depend on factors including the market dynamics of the CML treatment landscape.
The provided label excerpts do not address market dynamics or competition factors.
Contradictions
Important Omissions
The indication claim omits pediatric inclusion and does not state the full on-label adult/pediatric wording (CP newly-diagnosed and resistant/intolerant; and adult AP/BP with resistance/intolerance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported safety-relevant claim provided is general oral administration and indication; however, several unsupported broad class/mechanism and patent/market statements are not safety-critical relative to label content. No contraindication, warnings, or adverse-reaction claims were made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are outside the provided prescribing-information scope (FDA approval year and extensive patent/expiration/market-competition claims are not supported by the excerpts). The class/mechanism claims are also not explicitly supported by the excerpts.
Suggested Improvement
Limit claims to what is explicitly contained in the provided label excerpts (e.g., oral once-daily with food; the specific on-label indications and age/phase groupings). Remove or qualify any approval-date and patent/expiration/price-access predictions unless supported by label text.